专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2478371B1 Multimarker panel for left ventricular hypertrophy 有权
标题翻译： Multimarker-PanelfürLinksherzhypertrophie
公开(公告)号：EP2478371B1
公开(公告)日：2016-05-04
申请号：EP10752842.4
申请日：2010-09-16
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4712 , G01N2333/475 , G01N2333/58 , G01N2800/325 , G01N2800/52

2. 发明公开

EP2609427A1 USE OF BIOMARKERS IN THE ASSESSMENT OF THE EARLY TRANSITION FROM ARTERIAL HYPERTENSION TO HEART FAILURE 有权
标题翻译：使用生物标记物的从动脉高血压早期过渡的评估心脏衰竭
公开(公告)号：EP2609427A1
公开(公告)日：2013-07-03
申请号：EP11743231.0
申请日：2011-08-03
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , HÜDIG, Hendrik , VOGEL-ZIEBOLZ, Sabine , BÖHM, Christine , HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/53
CPC分类号： G01N33/54306 , G01N33/6887 , G01N33/6893 , G01N2333/4712 , G01N2333/495 , G01N2333/58 , G01N2800/325 , G01N2800/50 , G01N2800/52
摘要： The present invention relates to a method of diagnosing functional and/or structural abnormalities of the heart preceding heart failure, in a subject bearing risk factors of developing heart failure, the method comprising the steps of a) measuring in a sample obtained from the individual the concentration of at least one cardiac troponin, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) assessing functional and/or a structural abnormalities by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. The present invention also relates to a method of predicting the risk of a subject bearing risk factors of developing heart failure, to suffer from heart failure, the method comprising the steps of a) measuring in a sample obtained from the individual the concentration of at least one cardiac troponin, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) predicting the risk of the subjects to suffer from heart failure by comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample. The method, further characterized in that said one or more other marker is selected from the group consisting of a cardiac troponin marker, GDF 15 and insulin growth factor binding protein 7 (IGFBP7). In a preferred embodiment of the present invention, the subject suffers from left ventricular diastolic dysfunction. The present invention also relates to a method of deciding on the treatment of a subject bearing risk factors of developing heart failure and a method of monitoring the treatment. In preferred embodiments of the present invention, at least one further marker selected from: a cardiac troponin, GDF15 and IGFBP7. The present invention further relates to a method of monitoring treatment of functional and/or structural abnormalities of the heart preceding heart failure in a subject, the method comprising the steps of a) repeatedly determining, within given time intervals, the concentration of at least one cardiac troponin in at least one sample of said subject, b) optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and c) comparing the concentration determined in step (a) and optionally the concentration(s) determined in step (b) to the concentration of this marker or these markers as established in a control sample, and c) assessing, based on the differences in the determined concentrations in one or more of the above-cited markers, whether the subject has undergone a change in its pathophysiological state.

3. 发明公开

EP2583104A1 PREDICTION AND RECOGNITION OF ACUTE KIDNEY INJURY AFTER SURGERY 有权转让
标题翻译：预测和手术后检测急性肾损伤
公开(公告)号：EP2583104A1
公开(公告)日：2013-04-24
申请号：EP11725455.7
申请日：2011-06-15
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6872 , G01N33/74 , G01N2333/47 , G01N2333/475 , G01N2800/347 , G01N2800/56
摘要： The present invention relates to a method for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject, comprising the steps of: a) determining the amounts of liver-type fatty acid binding protein (L-FABP), in a urine-sample of a subject; b) comparing the amounts determined in step a) with reference amounts; and c) predicting the risk based on the comparison carried out in step b). Moreover, the present invention relates to a device and a kit for carrying out said method.

4. 发明公开

EP2786154A2 NT-PROANP AND NT-PROBNP FOR THE DIAGNOSIS OF STROKE 有权
标题翻译： NT-PRO-ANP UND NT-PRO-BNP ZUR DIAGNOSE EINES SCHLAGANFALLS
公开(公告)号：EP2786154A2
公开(公告)日：2014-10-08
申请号：EP12794941.0
申请日：2012-11-29
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/74 , G01N33/6893 , G01N33/6896 , G01N2333/58 , G01N2800/2871 , G01N2800/50
摘要： The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于诊断怀疑呈现短暂性缺血发作，但没有发生中风的受试者的短暂性缺血发作（TIA）的方法。该方法基于来自所述受试者的样品中NT-proANP的量的确定。此外，本发明涉及一种用于根据受试者样品中NT-proBNP和NT-proANP的量的测定来诊断受试者的急性脑缺血事件的方法。该方法还包括计算NT-proBNP和NT-proANP的量的比率的步骤。本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。

5. 发明公开

EP2769227A1 TROPONIN AND BNP BASED DIAGNOSIS OF RISK PATIENTS AND CAUSE OF STROKE 有权
标题翻译： AUF TROPONIN UND BNP BASIERENDE DIAGNOSE VON RISIKOPATIENTEN UND URSACHE EINES SCHLAGANFALLS
公开(公告)号：EP2769227A1
公开(公告)日：2014-08-27
申请号：EP12775484.4
申请日：2012-10-17
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , ZDUNEK, Dietmar , HORSCH, Andrea
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , G01N33/54306 , G01N33/6893 , G01N2333/47 , G01N2333/4712 , G01N2800/326
摘要： The present invention relates to a method for early differentiating whether a subject suffers from cardioembolic stroke or from non-cardioembolicischemic stroke. The method is based on the determination of the amount of a cardiac Troponin in a sample from a subject suffering from ischemic stroke obtained not more than 24 hours after the onset of symp- toms of ischemic stroke. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于诊断疑似患有心房颤动的人类受试者的间歇性房颤的方法，包括确定来自所述受试者的样品中心肌肌钙蛋白的量。本发明进一步设想的是适用于实施本发明方法的设备。

6. 发明公开

EP2504705A1 METHOD FOR DIAGNOSING AND MONITORING CARDIAC ISCHEMIA IN PATIENTS WITH ACUTE CHEST PAIN AND WITHOUT MYOCARDIAL INFARCTION 失效
标题翻译：方法对于与急性胸痛患者与无心肌梗死诊断与心脏缺血监测
公开(公告)号：EP2504705A1
公开(公告)日：2012-10-03
申请号：EP10784311.2
申请日：2010-11-29
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/68 , G01N33/74
CPC分类号： G01N33/6893 , G01N33/74 , G01N2333/4753 , G01N2333/71 , G01N2800/324
摘要： The present invention relates to a method for diagnosing the ischemic state in a subject who suffers from acute coronary syndrome and but not fulfilling the diagnostic criteria for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but not fulfilling the diagnostic criteria for a myocardial infarction. The methods of the present invention are based on the determination of fms-like tyrosine kinase-1 1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject and comparing the amount of sFLT-1 and, optionally, HGF to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.

7. 发明公开

EP2496946A1 NT-pro ANP AND SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS 失效
标题翻译： NT-pro ANP和SFlt-1用于循环和非缺血事件的区别
公开(公告)号：EP2496946A1
公开(公告)日：2012-09-12
申请号：EP10778941.4
申请日：2010-11-02
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , ZDUNEK, Dietmar , HORSCH, Andrea
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2333/71 , G01N2800/32 , G01N2800/347
摘要： The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.
摘要翻译：本发明涉及实验室诊断领域。具体而言，它公开了区分急性循环事件和缺血事件的手段和方法，作为患者急性医疗事件的潜在原因。

8. 发明授权

EP2496946B1 NT-pro ANP AND sFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS 失效
标题翻译： NT-pro ANP和sFlt-1用于循环和非缺血事件的区别
公开(公告)号：EP2496946B1
公开(公告)日：2015-07-15
申请号：EP10778941.4
申请日：2010-11-02
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , ZDUNEK, Dietmar , HORSCH, Andrea
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2333/71 , G01N2800/32 , G01N2800/347
摘要： The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.

9. 发明公开

EP2425255A1 MEANS AND METHODS FOR DIAGNOSING A HEART FAILURE ASSOCIATED KIDNEY DAMAGE IN INDIVIDUALS IN NEED OF A SUITABLE THERAPY 审中-公开
标题翻译：手段与方法心脏衰竭有关的肾损伤在一个适当的治疗要求个人诊断
公开(公告)号：EP2425255A1
公开(公告)日：2012-03-07
申请号：EP10715565.7
申请日：2010-04-29
申请人： Roche Diagnostics GmbH , F.Hoffmann-La Roche AG
发明人： HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/58 , G01N2800/325 , G01N2800/347
摘要： The present invention relates to a method for diagnosing kidney damage in a subject suffering from heart failure comprising the steps of: a) determining the amounts of liver-type fatty acid binding protein (L-FABP) and kidney injury molecule 1 (KIM-I) and optionally a natriuretic peptide in a sample of a subject; b) forming the L-FABP/KIM-1 ratio; c) comparing the amounts determined in step a) with reference amounts and diagnosing the kidney damage. Moreover, the present invention relates to a device and a kit for carrying out said method.

10. 发明公开

EP2321651A1 IDENTIFICATION OF SUBJECTS BEING SUSCEPTIBLE TO ANTI-ANGIOGENESIS THERAPY 有权
标题翻译：鉴定冯FÜREINE抗神经生物学家GEEIGNETEN PERSONEN
公开(公告)号：EP2321651A1
公开(公告)日：2011-05-18
申请号：EP09800069.8
申请日：2009-07-23
申请人： F.Hoffmann-La Roche AG , Roche Diagnostics GmbH
发明人： HESS, Georg , HORSCH, Andrea , ZDUNEK, Dietmar
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , A61P35/00 , C07K14/47 , C07K14/475 , C07K16/18 , C07K16/22 , G01N33/53 , G01N2333/4712 , G01N2333/58 , G01N2800/32 , G01N2800/52
摘要： The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于鉴定受抗体血管生成治疗敏感的受试者的方法，该方法基于确定受试者样品中心肌肌钙蛋白的量并将该量与合适的参考量进行比较。本发明还包括适用于实施本发明方法的试剂盒和装置。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式